RVMD
Revolution Medicines, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -1.8% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.20M | $451.04M | n/a | n/a |
| Q2 2026 | 149 | +17 | 106.82M | $18.63B | +25 | −7 |
| Q1 2026 | 134 | +17 | 103.45M | $9.43B | +22 | −6 |
| Q4 2025 | 116 | +1 | 107.70M | $8.12B | +3 | −1 |
| Q3 2025 | 20 | +3 | 68.96M | $3.10B | +3 | −1 |
| Q2 2025 | 15 | 0 | 63.88M | $2.26B | n/a | n/a |
| Q1 2025 | 12 | +2 | 32.32M | $1.05B | +2 | n/a |
| Q4 2024 | 10 | -1 | 33.19M | $1.34B | n/a | −1 |
| Q3 2024 | 10 | -1 | 26.28M | $1.08B | n/a | −1 |
| Q2 2024 | 11 | n/a | 28.23M | $999.53M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 15.76M | n/a | $579.87M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | Wellington Management ✦ | 10.26M | -13.0% | $377.46M | 0.1% | ▼ Trim | 5 | SEC ↗ ×9 |
| 3 | BlackRock ✦ (passive) | 8.66M | n/a | $318.65M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 4 | Fidelity (FMR) ✦ | 8.33M | n/a | $306.28M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 4.72M | -18.7% | $173.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 5.30M | -14.5% | $173.15M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 7 | Geode Capital Management ✦ (passive) | 2.99M | -27.7% | $110.16M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 1.70M | +21.2% | $62.58M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.48M | +1010.5% | $54.36M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 1.38M | +783.2% | $50.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 2.12M | +45.4% | $24.68M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 12 | Adage Capital Partners ✦ | 897.40K | +0.4% | $14.75M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Renaissance Technologies ✦ | 243.50K | +70.5% | $8.96M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 27.68K | -85.2% | $1.02M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 15.02K | +23.7% | $552,439 | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 509 holders, 197.96M shares, $18.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 765 sh · $158,600
Officer · 3.12K sh · $625,885
Officer · 587 sh · $117,400
Director · 910 sh · $174,585
Director · 4.99K sh · $959,805
Director · 1.50K sh · $291,883
Director · 100 sh · $19,515
Director · 2.65K sh · $512,227
Officer · 1.76K sh · $347,402
Officer, Director · 13.78K sh · $2.75M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology